Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Mikus

Showing results (11-20 of 194) with videos related to

Pageof 20
Sort By:
Clinical Pharmacology in Drug Development|January 2, 2019
Ketoconazole and Liver Injury: A Five-Year UpdateDavid J Greenblatt, Gerd Mikus
Expert Opinion on Pharmacotherapy|December 25, 2009
Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic painKatri Elina Clemens, Gerd Mikus
European Journal of Clinical Pharmacology|August 4, 2010
Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolamStephanie Katzenmaier, Christoph Markert, Gerd Mikus
Deutsches Arzteblatt International|March 26, 2014
Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicalsNicolas Hohmann, Gerd Mikus, David Czock
Rapid Communications in Mass Spectrometry : RCM|May 31, 2018
Isotopically labelled paroxetine standard allows for definite structure elucidation of the paroxetine tandem mass spectrumManuela Vay, Marius Majewsky, Gerd Mikus
Journal of Clinical Pharmacology|July 14, 2016
No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction StudiesNoémi Outeiro, Nicolas Hohmann, Gerd Mikus
Pharmacogenomics|June 23, 2011
Pharmacogenomics of the triazole antifungal agent voriconazoleGerd Mikus, Ina Maria Scholz, Johanna Weiss
Clinical Pharmacokinetics|May 1, 2015
Use of microdose phenotyping to individualise dosing of patientsNicolas Hohmann, Walter E Haefeli, Gerd Mikus
Expert Opinion on Drug Metabolism & Toxicology|March 8, 2016
CYP3A activity: towards dose adaptation to the individualNicolas Hohmann, Walter E Haefeli, Gerd Mikus
Palliative Medicine|April 27, 2019
Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3AMarcus Geist, Hubert Bardenheuer, Juergen Burhenne, et al.
Pageof 20

Showing results (11-20 of 194) with videos related to

Sort By:
Pageof 20
Clinical Pharmacology in Drug Development|January 2, 2019
Ketoconazole and Liver Injury: A Five-Year UpdateDavid J Greenblatt, Gerd Mikus
Expert Opinion on Pharmacotherapy|December 25, 2009
Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic painKatri Elina Clemens, Gerd Mikus
European Journal of Clinical Pharmacology|August 4, 2010
Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolamStephanie Katzenmaier, Christoph Markert, Gerd Mikus
Deutsches Arzteblatt International|March 26, 2014
Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicalsNicolas Hohmann, Gerd Mikus, David Czock
Rapid Communications in Mass Spectrometry : RCM|May 31, 2018
Isotopically labelled paroxetine standard allows for definite structure elucidation of the paroxetine tandem mass spectrumManuela Vay, Marius Majewsky, Gerd Mikus
Journal of Clinical Pharmacology|July 14, 2016
No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction StudiesNoémi Outeiro, Nicolas Hohmann, Gerd Mikus
Pharmacogenomics|June 23, 2011
Pharmacogenomics of the triazole antifungal agent voriconazoleGerd Mikus, Ina Maria Scholz, Johanna Weiss
Clinical Pharmacokinetics|May 1, 2015
Use of microdose phenotyping to individualise dosing of patientsNicolas Hohmann, Walter E Haefeli, Gerd Mikus
Expert Opinion on Drug Metabolism & Toxicology|March 8, 2016
CYP3A activity: towards dose adaptation to the individualNicolas Hohmann, Walter E Haefeli, Gerd Mikus
Palliative Medicine|April 27, 2019
Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3AMarcus Geist, Hubert Bardenheuer, Juergen Burhenne, et al.
Pageof 20